Tong C Maya, Baydoun Lamis, Melles Gerrit R J
aNetherlands Institute for Innovative Ocular Surgery, Rotterdam, The Netherlands bUniversity of Alberta, Edmonton, Alberta, Canada cMelles Cornea Clinic Rotterdam, Rotterdam, The Netherlands.
Curr Opin Ophthalmol. 2017 Jul;28(4):316-325. doi: 10.1097/ICU.0000000000000380.
Descemet membrane endothelial keratoplasty (DMEK) has become a first-line treatment in corneal endothelial diseases because of its exceptional clinical outcomes and low complication rates. Because of its improved refractive predictability, DMEK is now also considered for managing cases with endothelial decompensation following previous refractive procedures, or in combination with those. This article reviews the clinical outcomes in these cases and discusses the possibility of refractive interventions following DMEK.
DMEK has been successfully performed in eyes after laser in-situ keratomileusis, eyes after anterior chamber intraocular lens (IOL) implantation and aphakic eyes. Often, DMEK is combined with cataract surgery (triple-DMEK). Initial reports on reducing the refractive cylinder by toric IOL implantation are available. Although there are some reports on phacoemulsification and IOL implantation after phakic DMEK, reports on laser refractive procedures following DMEK are lacking.
In contrast to earlier keratoplasty techniques, DMEK induces on average only mild refractive shifts owing to the 'natural' restoration of the cornea. As such, DMEK may be ideal in managing corneal decompensation in refractive patients. However, further studies are required to assess the safety and efficacy of DMEK after refractive treatment and of refractive procedures following DMEK.
由于其卓越的临床效果和低并发症发生率,Descemet膜内皮角膜移植术(DMEK)已成为角膜内皮疾病的一线治疗方法。由于其屈光预测性的提高,DMEK现在也被考虑用于治疗先前屈光手术后继发内皮失代偿的病例,或与之联合使用。本文回顾了这些病例的临床结果,并讨论了DMEK术后屈光干预的可能性。
DMEK已成功应用于准分子原位角膜磨镶术术后眼、前房型人工晶状体(IOL)植入术后眼和无晶状体眼。通常,DMEK与白内障手术联合进行(三联DMEK)。有关于通过植入散光IOL降低屈光柱镜度数的初步报告。虽然有一些关于有晶状体眼DMEK术后超声乳化和IOL植入的报告,但缺乏关于DMEK术后激光屈光手术的报告。
与早期的角膜移植技术相比,由于角膜的“自然”修复,DMEK平均仅引起轻微的屈光变化。因此,DMEK可能是治疗屈光不正患者角膜失代偿的理想方法。然而,需要进一步研究来评估屈光治疗后DMEK以及DMEK术后屈光手术的安全性和有效性。